Figure legends
Figure 1. ODs for the treatment of Haemophilia A and B (n. 41).
Figure 2. Haemophilia ‘active’ ODs classification according to MOA (n. 26).
Figure 3. Mechanisms of action of novel non-factor therapeutics for haemophilia. Haemostatic nonfactor agents in varying phases of development include substitution therapies (Emicizumab) for FVIII that an restore factor Xa generation and rebalancing therapies, which knock down or disrupt the natural anticoagulants (small interfering RNA to AT and PS, monoclonal antibodies to TFPI), to augment haemostasis.